A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home

• Koichi HirataDokkyo Medical University
• Takao TakeshimaTominaga hospital
• Noboru ImaiShizuoka Red Cross Hospital
• Hisaka IgarashiFujitsu (Japan)
• Masako ShiosakaiOtsuka (Japan)
• Masanobu InageOtsuka (Japan)
• Fumi SakuraiOtsuka (Japan)
• Xiaoping NingTeva Pharmaceuticals (United States)
• Masami Nakai
• Nobuyuki Koga